In our previous study, we found that miR‐218 could target Glut1, activate the oxidative stress pathway in bladder cancer, and enhance the sensitivity of bladder cancer cells to cisplatin chemotherapy (Li et al., 2017). This evidence concerns the gene SLC2A1 and urinary bladder carcinoma.